Blocking the effect of interleukin-1 and tumor necrosis factor in rheumatoid arthritis is well tolerated and effective
| Autor: | Roy M Fleischmann |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
musculoskeletal diseases
Anakinra medicine.medical_specialty medicine.drug_class business.industry Antagonist Interleukin General Medicine Receptor antagonist medicine.disease Rheumatology Interleukin 1 receptor antagonist Internal medicine Rheumatoid arthritis Immunology medicine Pharmacology (medical) Tumor necrosis factor alpha business medicine.drug |
| Zdroj: | Therapy. 1:255-266 |
| ISSN: | 1744-831X 1475-0708 |
| DOI: | 10.2217/14750708.1.2.255 |
| Popis: | Interleukin (IL)-1 is a primary mediator in the pathophysiology of rheumatoid arthritis. Elevated IL-1 levels have been detected in the synovium of patients with rheumatoid arthritis and such elevated levels have been correlated with disease severity. In animal models, overexpression of IL-1 produces pathology closely resembling rheumatoid arthritis in humans. IL-1 receptor antagonist is an endogenous IL-1 antagonist. Genetically altered mice, designed to be deficient in IL-1 receptor antagonist, spontaneously develop a condition similar to rheumatoid arthritis. Anakinra is a recombinant human IL-1 receptor antagonist approved by the US Food and Drug Administration as a therapy for patients with rheumatoid arthritis. In clinical trials, patients receiving anakinra were more likely to achieve a higher response, as evaluated by the American College of Rheumatology criteria, than patients receiving placebo. Radiologic evaluation indicated a statistically significant slowing of cartilage destruction. Patients... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|